Mesothelioma  >>  Tecentriq (atezolizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
2017-003353-41: Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparibMiST 2 abemaciclibMiST 3 pembrolizumab in combination with bemcentinibMiST 4 atezolizumab in combination with bevacizumabMiST 5 dostarlimab in combination with niraparib

Not yet recruiting
2
120
Europe
rucaparib, abemaciclib, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), Pembrolizumab, bemcentinib, KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib, Dostarlimab, CO-338, LY2835219, R05541267/F03, RO4876646/F01, RO4876646/F02, MK-3475, BGB324, Tablet, Capsule, hard, Concentrate for solution for infusion, Solution for infusion, Capsule, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib
University of Leicester, The British Lung Foundation, Clovis Pharmaceuticals Inc., Eli Lilly & Company, Roche Pharma AG, Merck Sharp & Dohme Limited, BerGenBio ASA, GlaxoSmithKline Research & Development Limited
Malignant Mesothelioma (MM) - pleural and peritoneal, Mesothelioma is a universally lethal cancer caused by Asbestos. There has only been one licenced therapy since 2003. Accordingly there is a pressing need for effective therapy in the relapsed setting, Diseases [C] - Cancer [C04]
 
 
MiST, NCT03654833: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
MANTRA-4, NCT06090318: Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Withdrawn
1b/2
NA
Milademetan, RAIN-32, Atezolizumab, TECENTRIQ
Rain Oncology Inc
Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer
05/23
05/23
2021-003229-31: Integration of immunotherapy into first-line chemotherapy voor patients with epithelioid malignant pleural mesothelioma Toevoeging van immuuntherapie aan de eerstelijnschemotherapie voor patiënten met epitheliale longvlieskanker

Not yet recruiting
1/2
15
Europe
cryopreserved Wilms' tumor 1 (WT1) mRNA-electroporated dendritic cells, WT1/DC, Suspension for injection, Concentrate for solution for infusion, Tecentriq
Antwerp University Hospital, Kom op tegen Kanker, NV Roche SA
Malignant pleural mesothelioma, epithelioid subtype (stage I-IV) Maligne pleuraal mesothelioma, epithelioïde subtype (stadium I-IV), Asbestos cancer Asbestkanker (longvlieskanker), Diseases [C] - Cancer [C04]
 
 
NCT05944237: HTL0039732 in Participants With Advanced Solid Tumours

Recruiting
1/2
150
Europe
HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion
Cancer Research UK, Heptares Therapeutics Limited
Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
09/26
09/26
Immuno-MESODEC, NCT05765084: Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Recruiting
1/2
15
Europe
Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy
University Hospital, Antwerp, Algemeen Ziekenhuis Maria Middelares, Vitaz, Kom Op Tegen Kanker, Roche Pharma AG
Malignant Pleural Mesothelioma
10/26
10/26

Download Options